OKYO Pharma (OKYO) announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- Okyo Pharma reports results from Phase 2a trial of urcosimod
- OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
- OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
- Okyo Pharma initiated with an Overweight at Piper Sandler
- OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development